immunitoAI: The AI-Driven Solution for Novel Antibody Discovery

immunitoAI: The AI-Driven Solution for Novel Antibody Discovery – Antibodies are proteins that can bind to specific molecules, called antigens, and neutralize them. They are the key components of the immune system, and can be used as therapeutics for various diseases, such as cancer, autoimmune disorders, and infectious diseases. However, discovering and developing novel antibodies is a challenging and time-consuming process, that involves multiple steps, such as antigen selection, antibody generation, screening, optimization, and validation.

immunitoAI

Details of the startup:

  • CITY : Bengaluru
  • STATE : Karnataka
  • STARTED IN : 2020
  • FOUNDERS : Aridni Shah and Trisha Chatterjee
  • NUMBER OF INVESTORS : 3
  • LATEST ROUND INVESTMENT : –
  • TOTAL INVESTMENT : ₹73.50M
  •   TOTAL SECURED LOANS AVAILED : Nil

You can find their website here.

To overcome these challenges, immunitoAI, a biotech startup based in Bangalore, India, is using artificial intelligence (AI) and cloud computing to create a platform for antibody discovery and screening. The platform can generate novel antibodies with predefined drug properties, entirely using AI, and without relying on any biological source, animal or human, for the lead molecule. The platform can also screen and rank the best antibody candidates for a given target/antigen, using various in-silico (computational) methods.

Niramai: A Novel Breast Cancer Screening Solution

How does immunitoAI work?

immunitoAI was founded in 2020 by Dr. Aridni Shah and Trisha Chatterjee, who have backgrounds in biological sciences and computer science, respectively. They have a team of scientists, software engineers, and research associates, who work on developing and validating the AI platform for antibody discovery and screening.

The AI platform consists of two main modules: antibody generation and antibody screening. The antibody generation module uses deep learning and natural language processing techniques to generate de novo antibody and antibody fragments against any epitope, which is the part of the antigen that is recognized by the antibody. The module can produce diverse and novel antibody sequences, that are not limited by the existing antibody repertoire or libraries.

The antibody screening module uses machine learning and molecular modeling techniques to screen and rank the generated antibody candidates, based on various drug properties, such as affinity, specificity, stability, solubility, immunogenicity, and manufacturability. The module can also optimize the antibody candidates, by introducing mutations or modifications, to improve their drug properties.

The AI platform is integrated with an in-house biological lab, where the selected antibody candidates are experimentally validated, using various assays and techniques, such as ELISA, SPR, FACS, and cell-based assays. The lab also performs further optimization and characterization of the antibodies, before they are ready for preclinical and clinical trials.

B-Aegis: A Startup That Creates Innovative and Life-Changing Solutions for Cancer Patients

What are the advantages of immunitoAI?

immunitoAI has several advantages over the conventional methods of antibody discovery and development, such as:

  • Faster and cheaper: immunitoAI can generate and screen novel antibodies in a matter of weeks, compared to months or years required by the traditional methods. immunitoAI can also reduce the cost of antibody discovery and development, by eliminating the need for animal immunization, phage display, hybridoma, or other biological methods.
  • Better and smarter: immunitoAI can generate novel antibodies with predefined drug properties, that are not constrained by the existing antibody repertoire or libraries. immunitoAI can also screen and rank the best antibody candidates, using various in-silico methods, that are more accurate and reliable than the empirical methods.
  • Scalable and adaptable: immunitoAI can generate and screen antibodies against any target/antigen, regardless of its nature, origin, or availability. immunitoAI can also customize and optimize the antibodies, according to the specific needs and preferences of the customers or partners.
EndureAir: Taking Flight with Cutting-Edge Drone Solutions in India

How to collaborate with immunitoAI?

immunitoAI is open for collaboration with various stakeholders, such as biotech and pharma companies, academic and research institutions, and healthcare providers, who are interested in discovering and developing novel antibodies for various therapeutic applications. immunitoAI can offer various services, such as:

  • Generating novel antibodies against any target/antigen, with predefined drug properties, entirely using AI.
  • Screening and ranking the best antibody candidates, using various in-silico methods, and providing the antibody sequences and the drug property scores.
  • Experimentally validating the selected antibody candidates, using various assays and techniques, and providing the antibody clones and the validation data.
  • Optimizing and characterizing the validated antibodies, using various methods, and providing the optimized antibody sequences and the characterization data.

If you want to collaborate with immunitoAI, you can contact them through the following channels:

  • Website: 
  • Email: contact@immunitoai.com
  • Phone: +91 80 5032 7147
NAVA Design & Innovation: A Startup Company Focused on Social Innovations

immunitoAI is a biotech startup that aims to make targeted therapy using antibodies a norm. It is developing an AI-powered platform for antibody discovery and screening, that can generate novel antibodies with predefined drug properties, entirely using AI, and without relying on any biological source, animal or human, for the lead molecule. It can also screen and rank the best antibody candidates, using various in-silico methods, and experimentally validate and optimize them in their in-house lab.

If you are interested in discovering and developing novel antibodies for various therapeutic applications, you can collaborate with immunitoAI, and benefit from their faster, cheaper, better, and smarter solution. You can visit their website  or contact them at contact@immunitoai.com or +91 80 5032 7147 to get started. You can also follow them on social media LinkedIn , and to get the latest updates and news. immunitoAI is here to make antibody discovery and development easier and better.

You May Also Like

More From Author

+ There are no comments

Add yours